Vol. 3 No. 2 (2023)
Reimbursement Recommendations

Brolucizumab (Beovu)

Published February 8, 2023

Key Messages

  • CADTH recommends that Beovu be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met.
  • Beovu should be covered to treat patients with DME provided that Beovu is covered for a similar patient population and in a similar way to other anti–vascular endothelial growth factor (VEGF) drugs currently reimbursed by public drug plans for the treatment of adult patients with DME.
  • Beovu should only be reimbursed if prescribed by an ophthalmologist with experience in managing DME and if its cost is not more than the least costly anti-VEGF drug covered by the public drug plans for the treatment of DME.